Argenx price target raised to $130 from $100 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff raised his price target for Argenx to $130 after the company reached an agreement with FDA to initiate a single Phase III trial of efgartigimod in generalized myasthenia gravis this year. Full Phase II data presented at the American Academy of Neurology conference showed “rapid and durable clinical benefit,” Tenthoff tells investors in a research note. The analyst reiterates an Overweight rating on Argenx shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.